Home> Products> moderate renal impairment

{ "products": [ { "_id": "695b65af2800555f6696a6cf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Cinacalcet 60 mg Tablet", "description": "CINASELECT 60: Comprehensive Guide to Cinacalcet 60 mg Tablets\nProduct Overview\nCINASELECT 60 is a pharmaceutical formulation containing Cinacalcet hydrochloride 60 mg as its active ingredient. This medication represents a significant advancement in the management of calcium metabolism disorders, particularly in patients with chronic kidney disease and parathyroid conditions. As a calcimimetic agent, CINASELECT 60 works by mimicking the action of calcium on tissues, helping to restore hormonal balance and mineral homeostasis in the body.\nThe 60 mg dosage strength offers an effective therapeutic option for patients requiring moderate to higher-level intervention in managing parathyroid hormone levels and associated calcium imbalances. CINASELECT 60 is manufactured under strict quality control standards, ensuring consistency, purity, and efficacy in every tablet.\nUnderstanding How CINASELECT 60 Works\nCINASELECT 60 operates through a sophisticated mechanism that targets the calcium-sensing receptors located on the surface of parathyroid gland cells. These receptors play a crucial role in regulating parathyroid hormone secretion, which in turn controls calcium and phosphorus levels in the bloodstream.\nWhen you take CINASELECT 60, the active ingredient cinacalcet binds to these calcium-sensing receptors, increasing their sensitivity to extracellular calcium. This enhanced sensitivity tricks the parathyroid glands into “thinking” there is more calcium present in the blood than there actually is. As a result, the glands reduce their production and release of parathyroid hormone (PTH).\nBy lowering PTH levels, CINASELECT 60 subsequently reduces calcium levels in the blood and decreases the amount of phosphorus absorbed from the intestines. This cascade effect helps restore the delicate mineral balance that is often disrupted in patients with kidney disease or parathyroid disorders.\nPrimary Therapeutic Uses\nSecondary Hyperparathyroidism in Chronic Kidney Disease\nThe primary indication for CINASELECT 60 is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis. When kidneys fail to function properly, they cannot adequately regulate calcium and phosphorus levels, leading to excessive parathyroid hormone production. This condition can result in serious complications including bone disease, cardiovascular calcification, and increased mortality risk.\nCINASELECT 60 helps manage this condition by controlling PTH levels, thereby reducing the risk of bone complications such as osteitis fibrosa cystica and preventing the dangerous deposition of calcium in blood vessels and soft tissues.\nHypercalcemia in Parathyroid Carcinoma\nCINASELECT 60 is also indicated for treating hypercalcemia (elevated blood calcium levels) in patients with parathyroid carcinoma, a rare malignant tumor of the parathyroid glands. In these cases, the medication helps control the dangerously high calcium levels that can lead to kidney stones, bone pain, digestive issues, and neurological symptoms.\nPrimary Hyperparathyroidism\nFor patients with severe hypercalcemia due to primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery has failed, CINASELECT 60 offers a valuable medical management option. This provides relief for patients who are not surgical candidates due to advanced age, comorbidities, or other contraindications.\nKey Benefits of CINASELECT 60\nEffective PTH Control\nClinical studies have demonstrated that CINASELECT 60 significantly reduces parathyroid hormone levels in a dose-dependent manner. This reduction helps prevent the cascade of complications associated with elevated PTH, including bone mineral loss and cardiovascular calcification.\nImproved Calcium-Phosphorus Balance\nBy reducing PTH secretion, CINASELECT 60 helps normalize serum calcium and phosphorus levels. This is particularly important in dialysis patients, where mineral imbalances can lead to serious complications affecting bone health, cardiovascular function, and overall quality of life.\nReduced Cardiovascular Risk\nElevated calcium and phosphorus levels contribute to vascular calcification, a major risk factor for cardiovascular disease in patients with chronic kidney disease. By managing these mineral levels, CINASELECT 60 may help reduce the risk of cardiovascular complications, which are the leading cause of death in dialysis patients.\nBone Health Preservation\nUncontrolled secondary hyperparathyroidism leads to renal osteodystrophy, a condition characterized by abnormal bone metabolism. CINASELECT 60 helps protect bone integrity by normalizing PTH levels, potentially reducing fracture risk and preserving bone mineral density.\nAlternative to Surgery\nFor patients with primary hyperparathyroidism or parathyroid carcinoma who cannot undergo surgery, CINASELECT 60 provides an effective medical management option. This is particularly valuable for elderly patients or those with multiple comorbidities that make surgery risky.\nQuality of Life Improvement\nBy controlling symptoms associated with hypercalcemia and hyperparathyroidism, such as bone pain, muscle weakness, fatigue, and digestive issues, CINASELECT 60 can significantly improve patients' overall quality of life and functional capacity.\nConvenient Oral Administration\nCINASELECT 60 is administered orally, making it more convenient than injectable alternatives. This allows for outpatient management and reduces the burden on healthcare facilities and patients.\nPotential Side Effects and Adverse Reactions\nCommon Side Effects\nPatients taking CINASELECT 60 may experience several common side effects, which typically include nausea and vomiting, occurring in approximately 20-30% of patients. These gastrointestinal symptoms are usually mild to moderate and may improve over time as the body adjusts to the medication.\nDiarrhea is another frequent complaint, affecting roughly 20% of users. Some patients also report muscle pain or myalgia, dizziness, loss of appetite, and asthenia (general weakness or fatigue).\nSerious Side Effects Requiring Medical Attention\nHypocalcemia: The most significant risk associated with CINASELECT 60 is the development of low calcium levels in the blood. Severe hypocalcemia can lead to paresthesias (tingling sensations), muscle cramps or spasms, tetany, seizures, and QT interval prolongation on electrocardiogram, which can predispose to dangerous heart rhythm abnormalities.\nGastrointestinal Bleeding: There have been reports of gastrointestinal hemorrhage in patients taking cinacalcet, particularly in those with risk factors such as gastritis, ulcers, or concurrent use of other medications that increase bleeding risk.\nAdynamic Bone Disease: Oversuppression of PTH can lead to adynamic bone disease, a condition where bone turnover becomes abnormally low, potentially weakening bones despite normalized calcium levels.\nCardiovascular Effects: Some patients may experience worsening heart failure or arrhythmias, particularly if hypocalcemia develops. Close monitoring is essential in patients with underlying cardiovascular disease.\nAllergic Reactions: Though rare, hypersensitivity reactions including rash, urticaria, and angioedema have been reported.\nPrecautions and Contraindications\nCINASELECT 60 should not be used in patients with serum calcium levels below the normal range. It requires careful dose adjustment and monitoring in patients with hepatic impairment. The medication may interact with drugs metabolized by the CYP2D6 enzyme system and with medications that affect gastric pH.\nPregnant or breastfeeding women should use CINASELECT 60 only if clearly needed, as its safety in these populations has not been fully established. Regular monitoring of serum calcium, phosphorus, and PTH levels is essential throughout treatment.\nDosage and Administration Guidelines\nCINASELECT 60 should be taken orally with food or shortly after a meal, as this improves absorption and reduces gastrointestinal side effects. Tablets should be swallowed whole and not crushed, chewed, or divided.\nThe typical starting dose for secondary hyperparathyroidism is lower than 60 mg, with gradual titration based on PTH and calcium levels. The 60 mg strength is often used as part of the dose escalation process or as a maintenance dose once optimal PTH control is achieved.\nDose adjustments should be made no more frequently than every two to four weeks, as it takes this long to see the full effect of a dose change on PTH levels. Treatment should be individualized based on laboratory values and clinical response.\nMonitoring Requirements\nPatients on CINASELECT 60 require regular monitoring of serum calcium, phosphorus, and intact PTH levels. Calcium levels should be checked within one week of starting treatment or after any dose adjustment, and then monthly once stable. PTH levels should be measured one to four weeks after initiation or dose adjustment, then every one to three months during maintenance therapy.\nAdditionally, patients should be monitored for signs and symptoms of hypocalcemia, particularly during the initial treatment period. Electrocardiogram monitoring may be appropriate in patients at risk for QT prolongation.\nStorage and Handling\nCINASELECT 60 should be stored at room temperature, away from moisture and direct sunlight. The medication should be kept in its original container with the lid tightly closed to protect from humidity. Keep out of reach of children and pets. Do not use past the expiration date printed on the package.\nConclusion\nCINASELECT 60 (Cinacalcet 60 mg) represents a valuable therapeutic option in the management of secondary hyperparathyroidism associated with chronic kidney disease, hypercalcemia in parathyroid carcinoma, and primary hyperparathyroidism in patients who cannot undergo surgery. Its unique mechanism as a calcimimetic agent provides effective control of parathyroid hormone secretion, helping to restore mineral balance and prevent serious complications.\nThe benefits of CINASELECT 60 extend beyond simple laboratory value normalization. By controlling PTH, calcium, and phosphorus levels, this medication helps preserve bone health, reduce cardiovascular calcification risk, and improve overall quality of life for patients dealing with complex metabolic disorders. For patients who are not surgical candidates, CINASELECT 60 offers hope and effective symptom management.\nHowever, like all medications, CINASELECT 60 must be used judiciously under close medical supervision. The risk of hypocalcemia and other potential side effects necessitates regular laboratory monitoring and open communication between patients and healthcare providers. Patients should report any concerning symptoms promptly and attend all scheduled follow-up appointments.", "price": 740.0, "discountamount": 222.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2266, "imageuri": "https://productimages.withfloats.com/actual/695b65ebf30763183f64d4f7.png", "tileimageuri": "https://productimages.withfloats.com/tile/695b65ebf30763183f64d4f7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-05T07:18:07.264Z", "updatedon": "2026-05-01T06:30:26.075Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cinacalcet-60-mg-tablet/2266", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CINASELECT 60", "category": "NEPHROLOGYRANGE", "tags": [ "cinacalcet 60 mg", "cinacalcet mechanism of action.", "cinacalcet uses", "tab cinacalcet.", "cinacalcet dose.", "cinacalcet structure.", "cinacalcet tab.", "calcium and phosphorus levels in the bloodstream.", "parathyroid hormone secretion.", "calcium metabolism disorders.", "chronic kidney disease and parathyroid conditions.", "cinacalcet 60 mg", "cinacalcet 60", "Cinacalcet Tablets 60 mg price in India", "Buy Cinacalcet Tablets 60 mg online", "Cinacalcet 60 mg wholesale price", "Buy Cinacalcet Tablets 60 mg", "Get Cinacalcet Tablets 60 mg at best price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694cf85408591c1173b54c2f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Pregabalin Epalrestat and Methylcobalamin Tablets", "description": "EPSTATE ED represents an advanced pharmaceutical formulation that combines three powerful therapeutic agents: Pregabalin, Epalrestat, and Methylcobalamin. This innovative triple-combination medication is specifically designed to address the complex pathophysiology of diabetic neuropathy and neuropathic pain conditions. By integrating multiple mechanisms of action, EPSTATE ED offers a comprehensive approach to managing nerve-related complications that significantly impact the quality of life for millions of individuals worldwide.\nThe formulation addresses not only the symptomatic relief of neuropathic pain but also targets the underlying metabolic derangements that contribute to nerve damage progression. This multi-pronged therapeutic strategy makes EPSTATE ED particularly valuable for patients who require more than symptomatic management alone.\nUnderstanding the Active Components\nPregabalin: The Neuropathic Pain Modulator\nPregabalin serves as the cornerstone analgesic component in EPSTATE ED. This anticonvulsant medication works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. Through this mechanism, Pregabalin reduces the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This reduction in neurotransmitter release effectively dampens the abnormal neural signaling that characterizes neuropathic pain conditions.\nThe molecule demonstrates excellent bioavailability and rapid absorption, allowing patients to experience relief within a relatively short timeframe. Its efficacy in managing various neuropathic pain syndromes has been extensively documented in clinical trials, establishing it as a first-line agent for diabetic peripheral neuropathy, postherpetic neuralgia, and other chronic neuropathic pain conditions.\nEpalrestat: The Aldose Reductase Inhibitor\nEpalrestat represents a unique addition to the formulation, functioning as a selective aldose reductase inhibitor. In diabetic conditions, excess glucose is converted to sorbitol through the polyol pathway, with aldose reductase serving as the rate-limiting enzyme. The accumulation of sorbitol within nerve cells leads to osmotic stress, depletion of myoinositol, and subsequent nerve dysfunction.\nBy inhibiting aldose reductase, Epalrestat prevents this harmful sorbitol accumulation, thereby addressing one of the fundamental metabolic abnormalities responsible for diabetic neuropathy. This disease-modifying approach distinguishes EPSTATE ED from purely symptomatic treatments. Epalrestat has been particularly well-studied in Asian populations and has demonstrated the ability to improve nerve conduction velocities and reduce subjective neuropathic symptoms over time.\nMethylcobalamin: The Neurotropic Vitamin\nMethylcobalamin, the bioactive form of Vitamin B12, completes the therapeutic triad in EPSTATE ED. Unlike cyanocobalamin, which requires conversion in the body, methylcobalamin is immediately available for utilization in crucial biochemical processes. It plays an indispensable role in myelin synthesis, the protective sheath surrounding nerve fibers that enables proper signal transmission.\nThis coenzyme participates in methionine synthesis and is essential for maintaining the structural and functional integrity of neurons. Methylcobalamin also facilitates nerve regeneration and has demonstrated neuroprotective properties in various experimental models. For patients with diabetic neuropathy, who often exhibit Vitamin B12 deficiency (sometimes exacerbated by metformin therapy), supplementation with methylcobalamin addresses both nutritional deficits and supports nerve health at a fundamental level.\nClinical Applications and Uses\nEPSTATE ED is primarily indicated for the comprehensive management of diabetic peripheral neuropathy, a condition affecting approximately 50% of individuals with long-standing diabetes. The symptoms of this condition range from tingling sensations and burning pain to numbness and loss of protective sensation, which can lead to serious complications including foot ulcers and amputations.\nBeyond diabetic neuropathy, EPSTATE ED may be prescribed for various neuropathic pain syndromes where the combination of pain relief, metabolic correction, and nerve support proves beneficial. Patients experiencing chronic nerve pain resulting from metabolic disturbances, nutritional deficiencies, or structural nerve damage may find this combination particularly effective.\nThe medication is typically recommended for adults who have not achieved adequate symptom control with single-agent therapy or who would benefit from the synergistic effects of the three components. Healthcare providers may prescribe EPSTATE ED when a patient requires both immediate symptom relief and long-term disease modification.\nKey Benefits and Therapeutic Advantages\nComprehensive Multi-Mechanism Action\nThe primary advantage of EPSTATE ED lies in its multi-faceted approach to neuropathic conditions. Rather than addressing only pain symptoms, the formulation simultaneously tackles pain perception, underlying metabolic abnormalities, and nutritional support for nerve health. This comprehensive strategy may lead to superior outcomes compared to monotherapy approaches.\nEnhanced Pain Relief\nClinical evidence supporting Pregabalin's efficacy in neuropathic pain is substantial. Patients often report significant reductions in pain intensity, improved sleep quality due to decreased nocturnal pain, and enhanced ability to perform daily activities. The pain-relieving effects typically manifest within the first week of therapy and continue to improve with ongoing treatment.\nDisease Modification Potential\nUnlike purely symptomatic treatments, the inclusion of Epalrestat provides genuine disease-modifying potential. By targeting the polyol pathway, EPSTATE ED may slow the progression of nerve damage in diabetic patients. Long-term use may preserve nerve function and prevent the worsening of neuropathic symptoms, offering hope beyond mere symptom management.\nImproved Nerve Conduction and Function\nThe combination of metabolic correction through Epalrestat and neurotropic support via Methylcobalamin creates an environment conducive to nerve regeneration and functional improvement. Studies have demonstrated improvements in nerve conduction velocity parameters with similar combination therapies, suggesting potential restoration of nerve function rather than simple symptom masking.\nConvenience of Combination Therapy\nFor patients who would otherwise require multiple separate medications, EPSTATE ED offers the convenience of a single tablet containing all three therapeutic agents. This simplification of medication regimens improves compliance, reduces pill burden, and may enhance overall treatment outcomes.\nQuality of Life Enhancement\nThe cumulative effect of pain reduction, improved nerve function, and better metabolic control translates into meaningful quality of life improvements. Patients report better mobility, reduced interference of pain with daily activities, improved mood, and enhanced social functioning.\nPotential Side Effects and Safety Considerations\nCommon Side Effects\nAs with any pharmaceutical agent, EPSTATE ED may produce certain adverse effects. The most commonly reported side effects are primarily attributable to the Pregabalin component and include dizziness, somnolence, peripheral edema, dry mouth, blurred vision, weight gain, and difficulty with concentration or attention. These effects are generally mild to moderate and often diminish with continued therapy as the body adapts to the medication.\nGastrointestinal symptoms such as constipation or nausea may occur, though they are typically manageable with dietary modifications or symptomatic treatment. Some patients experience increased appetite leading to weight gain, which requires monitoring, particularly in diabetic individuals where weight management is crucial.\nSerious but Rare Adverse Events\nThough uncommon, certain serious adverse effects warrant immediate medical attention. These include allergic reactions manifesting as rash, itching, swelling, severe dizziness, or breathing difficulties. Pregabalin has been associated with rare cases of angioedema, which requires prompt discontinuation and medical intervention.\nMental health changes, including mood alterations, anxiety, depression, agitation, or suicidal thoughts, have been reported with Pregabalin use, particularly in individuals with pre-existing psychiatric conditions. Patients and caregivers should remain vigilant for behavioral changes and report them immediately to healthcare providers.\nDrug Interactions and Precautions\nEPSTATE ED may interact with other central nervous system depressants, including alcohol, opioids, benzodiazepines, and antihistamines, potentially intensifying sedation and cognitive impairment. Patients should inform their healthcare provider of all medications, supplements, and substances they consume.\nIndividuals with kidney impairment require dose adjustments since Pregabalin is primarily eliminated through renal excretion. Regular monitoring of renal function may be necessary during long-term therapy.\nSpecial Population Considerations\nPregnant or breastfeeding women should use EPSTATE ED only when clearly necessary and under strict medical supervision, as the safety profile in these populations has not been fully established. Elderly patients may be more susceptible to side effects, particularly dizziness and confusion, necessitating careful dose titration and monitoring.\nPatients should be advised against abrupt discontinuation of EPSTATE ED, as sudden cessation of Pregabalin may precipitate withdrawal symptoms including insomnia, nausea, headache, anxiety, and sweating. Gradual dose reduction under medical supervision is recommended when discontinuing therapy.\nDosage and Administration Guidelines\nThe appropriate dosage of EPSTATE ED is highly individualized and should be determined by a qualified healthcare professional based on the patient's specific condition, response to therapy, and tolerance. Typically, treatment begins with a lower dose that is gradually increased to achieve optimal therapeutic benefit while minimizing adverse effects.\nPatients should take EPSTATE ED exactly as prescribed, with or without food, at consistent times each day to maintain stable blood levels. Missing doses should be addressed by taking the forgotten dose as soon as remembered, unless it's nearly time for the next scheduled dose. Double dosing to compensate for missed doses is not recommended.\nRegular follow-up appointments allow healthcare providers to assess treatment efficacy, monitor for adverse effects, and make necessary dose adjustments. Patients should maintain open communication with their medical team regarding symptom improvement, side effects, and any concerns that arise during therapy.\nPatient Counseling and Lifestyle Recommendations\nMaximizing the benefits of EPSTATE ED extends beyond simply taking the medication. Patients should be counseled on complementary lifestyle measures that support neuropathy management. Maintaining optimal glycemic control remains paramount for diabetic patients, as blood sugar management directly impacts neuropathy progression regardless of medication.\nRegular physical activity, within individual capabilities, promotes circulation, supports nerve health, and may enhance the therapeutic effects of EPSTATE ED. Daily foot examinations become critical for diabetic patients to identify potential injuries early, preventing serious complications.\nNutritional optimization, including adequate intake of B vitamins, antioxidants, and essential nutrients, supports the neurotropic effects of Methylcobalamin. Avoiding alcohol and tobacco, both of which can exacerbate neuropathy, is strongly recommended.\nPatients should be cautioned about activities requiring alertness, such as driving or operating machinery, especially during the initial treatment phase when dizziness and somnolence may be more pronounced. These effects typically improve with continued therapy, but individual responses vary.\nConclusion\nEPSTATE ED represents a thoughtfully designed pharmaceutical formulation that addresses the multifaceted nature of diabetic neuropathy and neuropathic pain through its unique combination of Pregabalin, Epalrestat, and Methylcobalamin. This triple-action approach offers patients more than symptomatic relief—it provides genuine disease modification potential, nutritional support, and comprehensive nerve health optimization.\nThe synergistic effects of these three components create a therapeutic profile that is greater than the sum of its parts. While Pregabalin efficiently manages pain symptoms and improves quality of life in the short term, Epalrestat works to address underlying metabolic derangements that drive disease progression, and Methylcobalamin provides essential neurotropic support for nerve regeneration and function.\nFor patients struggling with the debilitating effects of neuropathic pain and diabetic neuropathy, EPSTATE ED offers renewed hope for better symptom control and potentially slowed disease progression. The convenience of combination therapy in a single tablet improves adherence and simplifies complex treatment regimens.\nHowever, EPSTATE ED is not without considerations. Potential side effects, though generally manageable, require awareness and monitoring. The medication is most effective when integrated into a comprehensive management plan that includes optimal glycemic control, lifestyle modifications, and regular medical supervision.\nUltimately, EPSTATE ED should be viewed as a valuable tool in the therapeutic arsenal against neuropathic conditions, best utilized under the guidance of knowledgeable healthcare professionals who can individualize treatment to each patient's unique needs and circumstances. With proper use, monitoring, and patient education, EPSTATE ED can significantly improve outcomes and quality of life for those affected by these challenging neurological conditions.", "price": 275.0, "discountamount": 82.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2253, "imageuri": "https://productimages.withfloats.com/actual/694cf859d25fa0b0657b1ac8.png", "tileimageuri": "https://productimages.withfloats.com/tile/694cf859d25fa0b0657b1ac8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T08:39:48.947Z", "updatedon": "2026-04-18T09:21:49.885Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//pregabalin-epalrestat-and-methylcobalamin-tablets/2253", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EPSTATE ED", "category": "NEUROLOGYRANGE", "tags": [ "regabalin, Epalrestat, and Methylcobalamin.neuropathic pain conditions.", "Pregabalin, Epalrestat, and Methylcobalamin.", "neuropathic pain.", "diabetic neuropathy.", "sorbitol within nerve cells leads to osmotic stress.", "Epalrestat and neurotropic support via Methylcobalamin creates an environment .", "mood alterations, anxiety, depression, agitation.", "supports the neurotropic effects of Methylcobalamin.", "Pregabalin Epalrestat and Methylcobalamin Tablets", "epalrestat and methylcobalamin tablets uses", "epalrestat and methylcobalamin tablets in hindi", "pregabalin epalrestat and methylcobalamin tablets price jaipur", "pregabalin epalrestat and methylcobalamin tablets price india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694919f0de5d3e57a93413a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "elagolix 150mg tablet", "description": "Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain.\n\nTake Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care.\n\nPrimary Uses and Indications\nEligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression.\n​\nPrescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization.\n​\nMechanism of Action\nElagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing.\n​\nUnlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies.\n\nKey Benefits\nEligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments.\n​\nExtended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses.\n\nBenefit\tTrial Data\tPatient Impact\nPain Reduction\t32-50% dysmenorrhea-free \n​\tDaily activity restoration\nBleeding Control\t70% volume drop \n​\tAnemia prevention\nLong-Term Use:\tUp to 24 months \n​\tSustained relief\nQoL Improvement\tEQ-5D gains \n​\tEmotional well-being\nPotential Side Effects\nVasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1.\n​\nBMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%.\n\nSide Effect\tIncidence\tMitigation\nHot Flashes\t20-30% \n​\tVentilation, timing\nHeadache\t17% \n​\tAnalgesics\nBMD Loss\t0.9% \n​\tSupplements, scans\nMood Shifts\t5% \n​\tMonitoring\nSerious Risks and Management\nSuicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35.\n​\n\nDosage Guidelines\n150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily.\n​\n\nPrecautions and Contraindications\nPregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated.\n​\nClinical Evidence and Efficacy\nElaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain.\n​\nConclusion\nEligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.\n", "price": 700.0, "discountamount": 210.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2252, "imageuri": "https://productimages.withfloats.com/actual/694a2af01e4092f757d90bb5.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2af01e4092f757d90bb5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T10:14:08.773Z", "updatedon": "2026-03-26T05:59:45.544Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//elagolix-150mg-tablet/2252", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 150", "category": "GYANECOLOGYRANGE", "tags": [ "elagolix 150mg tablet", "prioritizing bone health.", "endometriotic pain.", "endometrial tissue proliferation outside the uterus.", "Eligolux 150 empowers women with moderate endometriosis pain through precise.", "hormonal modulation and proven outcomes.", "gonadotropins.", "endometriotic pain." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d6df52731125bdd4e1003b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VALGANCICLOVIR TABLET 450 MG", "description": "VOLANE SOURCE 450 is a pharmaceutical tablet containing Valganciclovir at a dosage strength of 450 mg. It is a potent antiviral medication primarily designed to treat and prevent certain viral infections caused by cytomegalovirus (CMV), especially in immunocompromised patients such as those undergoing organ transplants or living with HIV/AIDS. Manufactured adhering to strict quality standards under the tablet IP (Indian Pharmacopoeia), VOLANE SOURCE 450 ensures consistent efficacy and safety for patients requiring antiviral therapy.\n\nComposition and Pharmacological Profile\nEach film-coated tablet of VOLANE SOURCE 450 contains 450 mg of Valganciclovir as the active ingredient. Valganciclovir is a prodrug of ganciclovir, meaning it is converted in the body into ganciclovir, which is the active antiviral agent. Its mechanism involves inhibiting viral DNA synthesis by competing with deoxyguanosine triphosphate for incorporation into viral DNA, thereby suppressing the replication of CMV and related herpes viruses.\n\nPrimary Uses of VOLANE SOURCE 450\nTreatment of CMV Retinitis: CMV retinitis is a serious viral eye infection common in patients with weakened immune systems, such as AIDS patients. It leads to inflammation and possible vision loss if left untreated. VOLANE SOURCE 450 is a frontline therapy used to halt the progression of this infection.\n\nPrevention of CMV Disease in Transplant Patients: Solid organ transplant recipients and bone marrow transplant patients are at high risk of CMV infection due to immunosuppressive drugs. Prophylactic use of VOLANE SOURCE 450 helps in preventing CMV disease in these vulnerable groups.\n\nTreatment of CMV Infection: Apart from retinitis, CMV can cause systemic infections affecting multiple organs, including lungs, digestive tract, and nervous system. VOLANE SOURCE 450 is used for managing such infections effectively.\n\nPart of Combination Therapy: It may also be prescribed alongside other antiviral agents as part of combination treatment protocols tailored to complex viral infections, enhancing viral suppression.\n\nKey Benefits of Using VOLANE SOURCE 450\nHigh Oral Bioavailability: Being a prodrug, Valganciclovir is well absorbed orally and converted efficiently to ganciclovir in the body, enabling effective antiviral levels.\n\nWide Spectrum of Action: Targets multiple herpesviruses with high specificity, primarily cytomegalovirus, reducing viral load and infection severity.\n\nReduced Risk of CMV Disease Post-Transplant: By preventing CMV infection in transplant recipients, VOLANE SOURCE 450 significantly lowers the risk of post-transplant complications related to viral disease.\n\nConvenient Oral Dosage: Unlike intravenous ganciclovir, VOLANE SOURCE 450 allows for easier home administration, improving patient compliance and quality of life.\n\nEffective Against Resistant Strains: Used in recurrent and resistant CMV infections, especially where other therapies fail.\n\nProtects Vision: In CMV retinitis patients, prompt use of VOLANE SOURCE 450 can preserve vision and prevent blindness due to viral damage.\n\nRecommended Dosage and Administration\nThe dosing of VOLANE SOURCE 450 depends on the condition being treated, kidney function, and patient immune status. It is typically prescribed by healthcare professionals following careful medical assessment.\n\nFor CMV retinitis treatment, the initial dose is usually higher and then tapered down for maintenance.\n\nFor CMV prophylaxis post-transplant, a standard dose is taken once or twice daily for several months.\n\nIt is advised to swallow tablets whole with food to enhance absorption.\n\nRegular monitoring of blood counts and kidney function is essential during therapy since the drug can impact bone marrow and renal function.\n\nPotential Side Effects of VOLANE SOURCE 450\nLike any potent antiviral medication, VOLANE SOURCE 450 can cause side effects. Awareness and timely reporting to a healthcare provider are important to manage these effects safely.\n\nCommon side effects include:\n\nGastrointestinal symptoms: Nausea, vomiting, diarrhea, and abdominal pain.\n\nBone marrow suppression: Leading to anemia, neutropenia (low neutrophils), or thrombocytopenia (low platelets), which increase infection risks and bruising.\n\nHeadache and fatigue: Mild to moderate headache and tiredness may occur.\n\nFever and infections: Due to immune suppression, secondary infections may arise.\n\nElectrolyte imbalance: Occasionally, abnormalities in blood calcium or potassium levels.\n\nRare hypersensitivity reactions: Skin rash, itching, or swelling which require immediate medical attention.\n\nPrecautions and Contraindications\nPatients with severe renal impairment require dose adjustments or alternative therapies to avoid toxicity.\n\nPregnant or breastfeeding women should avoid this drug due to potential harm to the fetus or infant.\n\nRegular blood tests are necessary to monitor for hematologic or renal side effects.\n\nUse caution in patients with pre-existing neutropenia or anemia.\n\nConclusion\nVOLANE SOURCE 450 (Valganciclovir Tablet IP 450 mg) represents a reliable and efficacious antiviral therapy specifically targeting cytomegalovirus infections. Its role in treatment and prevention of CMV-related diseases, especially among immunocompromised patients, makes it invaluable in clinical practice.\n\nIts oral formulation allows for easy administration and effective drug delivery, improving patient adherence and outcomes. While the risk of side effects exists, careful monitoring and adherence to prescribed dosages minimize complications.\n\nOverall, VOLANE SOURCE 450 offers a potent solution against serious viral infections, helping preserve health, prevent complications, and improve quality of life for vulnerable patient populations.\n\n", "price": 3944.0, "discountamount": 2367.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "viral DNA", "rare cases", "Key Benefits", "CMV Retinitis", "VOLANE SOURCE", "CMV infection", "various organs", "kidney function", "prescribed course", "chain termination", "active ingredient", "organ transplants", "medical condition", "blood cell counts", "healthcare provider", "severe side effects", "Common Side Effects", "Regular blood tests", "complete eradication", "antiviral medication", "high bioavailability", "severe eye infection", "Serious Side Effects", "high-risk individuals", "convenient oral option", "bone marrow suppression", "weakened immune systems", "VALGANCICLOVIR TABLET IP", "High Oral Bioavailability", "Immediate medical attention" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1950, "imageuri": "https://productimages.withfloats.com/actual/6936b55236477d52c1e94700.png", "tileimageuri": "https://productimages.withfloats.com/tile/6936b55236477d52c1e94700.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-03T10:05:06.943Z", "updatedon": "2026-03-12T06:40:40.942Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//valganciclovir-tablet-450-mg/1950", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOLANE SOURCE 450", "category": "CARDIOLOGYRANGE", "tags": [ "VALGANCICLOVIR TABLET IP 450 MG USUE", "Valganciclovir Tablet IP 450 mg", "infections caused by cytomegalovirus (CMV).", "VOLANE SOURCE 450", "helps control the spread of the CMV infection within the body", "high bioavailability", "improve quality of life for vulnerable patient populations", "valganciclovir tablet 450 mg uses", "valganciclovir 450 mg tablet price in India", "valganciclovir 450 mg dosage information", "valganciclovir tablet 450 mg composition", "valganciclovir 450 mg tablet side effects", "valganciclovir 450 mg tablet benefits", "what is valganciclovir tablet 450 mg used for", "how valganciclovir 450 mg works", "valganciclovir 450 mg tablet mechanism of action", "valganciclovir tablet 450 mg storage instructions", "valganciclovir 450 mg tablet administration guide", "buy valganciclovir 450 mg tablet online", "valganciclovir 450 mg tablet supplier India", "valganciclovir tablet 450 mg wholesale price", "valganciclovir 450 mg tablet manufacturer", "valganciclovir 450 mg tablet distributor", "valganciclovir 450 mg generic tablet", "valganciclovir 450 mg tablet substitute", "valganciclovir 450 mg antiviral tablet", "when to take valganciclovir 450 mg tablet" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661a73687f0960e14a2c739", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "mycophenolate sodium 360 mg", "description": "MYCOPLASM S 360 \nMycophenolate sodium 360 mg is an essential immunosuppressant medication designed to prevent organ transplant rejection, particularly for kidney, heart, and liver transplants. As the sodium salt of mycophenolic acid, it delivers 360 mg of the active moiety per tablet, providing targeted immune suppression to help patients maintain their new organs long-term. This product stands out for its enteric-coated formulation, which enhances gastrointestinal tolerability compared to other forms, making it a preferred choice in post-transplant care regimens.​\n\nUses of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg primarily serves as a prophylactic agent against acute rejection in adult and pediatric patients receiving allogeneic renal, cardiac, or hepatic transplants. It works alongside other immunosuppressants like cyclosporine and corticosteroids to create a balanced regimen that minimizes the risk of graft loss. Clinically, it proves effective in de novo transplant recipients, where starting therapy early post-surgery significantly reduces rejection episodes. Beyond transplants, off-label applications include managing refractory autoimmune conditions such as lupus nephritis or myasthenia gravis, where immune overactivity damages tissues.​\n\nThe drug targets the proliferation of T- and B-lymphocytes, key players in immune responses that can attack transplanted organs. In renal transplant patients, for instance, it helps preserve kidney function by curbing antibody-mediated rejection. Its role extends to maintenance therapy, where consistent dosing sustains immunosuppression without excessive toxicity. Healthcare providers often adjust it based on patient response and trough levels of the active metabolite, mycophenolic acid (MPA), ensuring optimal therapeutic outcomes.​\n\nKey Benefits of Mycophenolate Sodium 360 mg\nMycophenolate sodium 360 mg offers several advantages that make it a cornerstone in transplant medicine. One primary benefit is its selective inhibition of lymphocyte proliferation, sparing other cell types and reducing broad-spectrum immunosuppression risks. This leads to fewer opportunistic infections compared to older agents like azathioprine. The enteric coating minimizes upper GI upset, improving patient compliance—studies show higher adherence rates with this formulation.​\n\nEnhanced Graft Survival: Prolongs organ viability by effectively suppressing cell-mediated and humoral immunity, with clinical data showing reduced biopsy-proven rejection rates.\n\nImproved Tolerability: Lower incidence of nausea and diarrhea due to delayed-release technology, allowing twice-daily dosing without food restrictions.\n\nFlexible Dosing: Equivalent to 720 mg mycophenolate mofetil, but with predictable MPA exposure via enterohepatic recirculation for steady-state efficacy.\n\nPediatric Suitability: Approved for children over 2 years in renal transplants, supporting growth without compromising safety.\n\nCost-Effective Long-Term Option: Balances efficacy and side effect profile, potentially lowering overall healthcare costs from fewer rejections or hospitalizations.​\n\nPatients experience better quality of life, with sustained energy levels and fewer interruptions from acute rejection crises. Its metabolism to MPA via liver glucuronidation ensures reliable pharmacokinetics, even in patients with mild renal impairment.​\n\nSide Effects of Mycophenolate Sodium 360 mg\nWhile highly effective, mycophenolate sodium 360 mg carries risks typical of immunosuppressants, necessitating vigilant monitoring. Common adverse effects stem from its impact on rapidly dividing cells, particularly in the gut and bone marrow.\n\nCommon Side Effects\nGastrointestinal issues like diarrhea, nausea, vomiting, and abdominal pain, affecting up to 30-50% of users.\n\nHeadache, insomnia, and tremor, often mild and transient.\n\nInfections such as urinary tract or respiratory, due to moderated immunity.\n\nHypertension or peripheral edema, manageable with supportive care.\n\nLeukopenia or anemia, requiring periodic blood counts.​\n\nSerious Side Effects\nSevere myelosuppression leading to neutropenia or thrombocytopenia, which can increase infection or bleeding risks.\n\nProgressive multifocal leukoencephalopathy (PML), a rare brain infection linked to JC virus reactivation.\n\nGastrointestinal perforation or bleeding, especially in at-risk patients.\n\nIncreased malignancy risk, including lymphoma or skin cancers, over long-term use.\n\nHypersensitivity reactions like rash or anaphylaxis.​\n\nRegular complete blood counts, viral monitoring (e.g., CMV, BK virus), and skin exams mitigate these risks. Dose reductions or discontinuation may be needed if counts drop significantly.​\n\nMechanism of Action\nMycophenolate sodium 360 mg rapidly hydrolyzes to mycophenolic acid (MPA), a potent, reversible, non-competitive inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH). This enzyme catalyzes the rate-limiting step in de novo guanine nucleotide synthesis, depleting guanosine nucleotides essential for T- and B-cell DNA replication. Lymphocytes, reliant on this pathway, undergo proliferation arrest, suppressing both cell-mediated immunity and antibody production.​\n\nMPA also hinders glycosylation of adhesion molecules on lymphocytes and monocytes, impeding their migration to graft sites. It reduces nitric oxide production in macrophages without affecting endothelial cells, curbing inflammation. Enterohepatic recirculation of the glucuronide metabolite (MPAG) prolongs MPA exposure, enhancing efficacy. Protein binding to albumin (around 97%) ensures targeted delivery, with clearance primarily renal for the inactive form.​\n\nDosage and Administration Guidelines\nStandard dosing for renal transplant is 720 mg (two 360 mg tablets) twice daily, starting within 72 hours post-surgery. Adjustments occur for hepatic or cardiac transplants, often alongside cyclosporine. Therapeutic drug monitoring of MPA AUC (area under curve) optimizes levels between 30-60 mcg·h/mL. Take on an empty stomach for best absorption, though food has minimal impact due to the coating.​\n\nPrecautions and Warnings\nAvoid in pregnancy (Category D) due to teratogenicity—use contraception and regular pregnancy tests. Contraindicated in active untreated infections. Monitor for GI bleeding in ulcerative colitis patients. Drug interactions with antacids, cholestyramine, or rifampin alter MPA levels. Live vaccines are prohibited.​\n\nConclusion\nMycophenolate sodium 360 mg represents a vital advancement in transplant immunosuppression, offering robust protection against rejection with a favorable benefit-risk profile. Its targeted action on lymphocytes, combined with improved GI tolerance, empowers patients to thrive post-transplant. By integrating it into comprehensive regimens with close monitoring, healthcare teams maximize graft success and patient well-being. Always consult a specialist for personalized guidance to harness its full potential safely.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \nhttps://www.sterisonline.com/product/mycoplasm-s-360-133670\n\n\n\n\n\n\n", "price": 767.0, "discountamount": 567.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dose", "risk", "body", "part", "ORDER", "360mg", "Email", "cells", "dosage", "nausea", "vomiting", "schedule", "headache", "strength", "WhatsApp", "diarrhea", "activity", "rejection", "treatment", "infections", "supplements", "information", "MYCOPLASM S", "sterispharma", "sterisonline", "stomach pain", "blood counts", "immune system", "complications", "liver problems", "liver function", "other medications", "Regular monitoring", "medical conditions", "healthcare provider", "Common side effects", "Serious side effects", "white blood cell count", "potential drug interactions", "optimal therapeutic effects", "combination therapy regimen", "organ transplant recipients", "Mycophenolate Sodium therapy", "other immunosuppressive drugs" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1474, "imageuri": "https://productimages.withfloats.com/actual/6661a739c749b7962dbc08c6.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661a739c749b7962dbc08c6.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:10:30.488Z", "updatedon": "2026-03-12T08:02:36.733Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//mycophenolate-sodium-360-mg/1474", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MYCOPLASM S 360 ", "category": "Oncology", "tags": [ "MYCOPLASM S 360", "Mycophenolate sodium (360mg)", "Mycophenolate sodium 360 mg price", "Mycophenolate sodium 360 mg brands", "Mycophenolate sodium 360 mg side effects", "Myfortic 360 alternative", "Myfortic 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "666163aa8e599e12c0eaa3bc", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Cephalexin 375mg", "description": "CEPHAHELIX 375 \nCephalexin 375mg\nIntroduction to Cephalexin 375mg\n\nCEPHAHELIX 375 is a highly effective antibiotic formulation containing Cephalexin 375 mg. It belongs to the cephalosporin class of antibiotics, widely prescribed for treating a variety of bacterial infections. This medicine works by eliminating harmful bacteria from the body, helping patients recover quickly and safely.\n\nHealthcare professionals trust CEPHAHELIX 375 for its proven efficacy, safety profile, and broad-spectrum antibacterial activity. It is commonly used in clinical settings for both mild and moderate infections.\n\nHow CEPHAHELIX 375 Works\n\nCephalexin works by targeting the bacterial cell wall. It interferes with the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Without a properly formed cell wall, bacteria cannot survive, leading to their destruction.\n\nThis mechanism makes CEPHAHELIX 375 bactericidal (kills bacteria) rather than bacteriostatic (just inhibits growth), ensuring faster infection control.\n\nUses of CEPHAHELIX 375\n\nCEPHAHELIX 375 is widely prescribed for treating several bacterial infections, including:\n\n1. Respiratory Tract Infections\nBronchitis\nPneumonia\nThroat infections (like tonsillitis and pharyngitis)\n2. Skin and Soft Tissue Infections\nCellulitis\nBoils and abscesses\nWound infections\n3. Urinary Tract Infections (UTIs)\nCystitis\nPyelonephritis (mild cases)\n4. Ear and Sinus Infections\nOtitis media\nSinusitis\n5. Bone Infections\nOsteomyelitis (as part of combination therapy)\n\nCEPHAHELIX 375 is effective against both Gram-positive and some Gram-negative bacteria, making it a versatile antibiotic option.\n\nKey Benefits of CEPHAHELIX 375\n1. Broad-Spectrum Antibiotic\n\nCephalexin effectively targets a wide range of bacteria, making it suitable for multiple types of infections.\n\n2. Fast Action\n\nPatients often start experiencing symptom relief within a few days of starting the medication.\n\n3. Well-Tolerated\n\nCompared to many antibiotics, Cephalexin has a relatively low incidence of severe side effects.\n\n4. High Patient Compliance\n\nAvailable in convenient oral dosage forms, CEPHAHELIX 375 is easy to administer.\n\n5. Effective for Recurrent Infections\n\nIt is often prescribed in cases of recurring infections due to its reliable efficacy.\n\n6. Suitable for Various Age Groups\n\nWith proper dosage adjustments, it can be used in both adults and children (as prescribed by a doctor).\n\nDosage and Administration\nThe dosage of CEPHAHELIX 375 depends on the severity and type of infection.\nTypically taken 2–4 times a day as directed by a physician.\nIt can be taken with or without food, although taking it with food may reduce stomach upset.\nComplete the full course even if symptoms improve early to prevent antibiotic resistance.\nPossible Side Effects of CEPHAHELIX 375\n\nLike all medications, CEPHAHELIX 375 may cause some side effects. Most are mild and temporary.\n\nCommon Side Effects\nNausea\nVomiting\nDiarrhea\nAbdominal pain\nIndigestion\nLess Common Side Effects\nSkin rash\nDizziness\nFatigue\nRare but Serious Side Effects\nSevere allergic reactions (anaphylaxis)\nClostridium difficile-associated diarrhea\nLiver function changes\n\nIf any severe or persistent side effects occur, medical attention should be sought immediately.\n\nPrecautions and Warnings\nAllergy Alert: Avoid if allergic to cephalosporins or penicillin-type antibiotics.\nKidney Disorders: Dose adjustment may be required in patients with renal impairment.\nPregnancy & Breastfeeding: Use only under medical supervision.\nDrug Interactions: Inform your doctor about all medications you are taking.\nStorage Instructions\nStore in a cool, dry place away from direct sunlight.\nKeep out of reach of children.\nDo not use after the expiry date.\nWhy Choose CEPHAHELIX 375?\n\nCEPHAHELIX 375 stands out in the pharmaceutical market due to the following:\n\nReliable quality formulation\nConsistent therapeutic outcomes\nCost-effective antibiotic solution\nTrusted by healthcare professionals\n\nIt is an ideal choice for hospitals, clinics, and pharmacies looking for dependable antibiotic products.\n\nConclusion\n\nCEPHAHELIX 375 (Cephalexin 375mg) is a powerful and dependable antibiotic designed to treat a wide range of bacterial infections effectively. Its fast-acting mechanism, broad-spectrum activity, and favorable safety profile make it a preferred choice among healthcare providers.\n\n\n\n\n\n\n", "price": 178.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Call", "bone", "skin", "Email", "375mg", "growth", "nausea", "dosage", "doctor", "variety", "diarrhea", "concerns", "WhatsApp", "vomiting", "treatment", "Cephalexin", "medication", "antibiotic", "CEPHAHELIX", "information", "full course", "sterispharma", "sterisonline", "Side effects", "urinary tract", "respiratory tract", "allergic reactions", "healthcare provider", "bacterial infections" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1414, "imageuri": "https://productimages.withfloats.com/actual/666163ae4328177af1cfeadb.png", "tileimageuri": "https://productimages.withfloats.com/tile/666163ae4328177af1cfeadb.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:22:18.57Z", "updatedon": "2026-04-06T06:42:15.26Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//cephalexin-375mg/1414", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CEPHAHELIX 375 ", "category": "GENERAL RANGE", "tags": [ "cephalexin 375", "cephalexin 375 mg", "cephalexin 375 mg uses in hindi", "cephalexin 375 mg tablet", "cephalexin 375 mg uses", "cephalexin 375 mg price in india", "buy cephalexin 375 mg online india", "cephalexin 375 mg bulk order manufacturer", "cephalexin 375 mg best price supplier", "cephalexin 375 mg how to use" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6a7722af7f45a0190eb37920", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Tolperisone Hydrochloride & Paracetamol Tablets", "description": "TOPERITIME P 150/325: Dual-Action Relief for Musculoskeletal Pain and Spasms\nTOPERITIME P 150/325 is a prescription combination therapy formulated to treat acute musculoskeletal discomfort, muscle stiffness, and associated inflammatory pain. By uniting a centrally acting muscle relaxant with a proven analgesic, this film-coated tablet addresses both the neurological and physical aspects of muscle strain, restoring movement and facilitating recovery.\n\nActive Ingredients\nEach film-coated tablet contains:\n\nTolperisone Hydrochloride (150 mg): A muscle relaxant targeting involuntary contractions within the central nervous system.\n\nParacetamol (325 mg): A widely recognized analgesic and antipyretic agent that blocks pain signal transmission.\n\nAvailable in blister packaging and dispensed strictly under a licensed physician's order.\n\nTherapeutic Mechanism\nPainful muscle conditions often create a feedback loop where localized pain triggers involuntary spasms, which in turn exacerbate the pain. TOPERITIME P 150/325 disrupts this cycle through a two-pronged mechanism:\n\nNeuromuscular Regulation: Tolperisone Hydrochloride acts on the spinal cord and brainstem reflexes to inhibit hyperactive nerve impulses driving muscle tension. Unlike traditional skeletal muscle relaxants, it achieves this with minimal central nervous system depression, significantly reducing the likelihood of heavy sedation.\n\nNociceptive Blocking: Paracetamol inhibits prostaglandin synthesis within the central nervous system, raising the body's overall pain threshold and attenuating pain signals originating from injured tissues.\n\nBy simultaneously relaxing tight muscle fibers and dampening pain sensation, the formulation provides comprehensive symptomatic relief.\n\nClinical Indications\nHealthcare professionals may prescribe TOPERITIME P 150/325 for various acute and subacute conditions characterized by pain and hypertonia, including:\n\nAcute muscle spasms and athletic injuries\n\nAcute or chronic lower back pain (lumbago)\n\nCervical spine discomfort and stiff neck\n\nCervical and lumbar spondylosis\n\nFrozen shoulder (adhesive capsulitis)\n\nPost-operative or post-traumatic muscle recovery\n\nGeneralized connective tissue or orthopedic pain\n\nKey Clinical Features\nBalanced Dual Action: Simultaneously targets involuntary contractions and pain sensation.\n\nLow-Sedation Profile: Tolperisone allows patients to maintain daily function without severe daytime drowsiness typical of older relaxants.\n\nEnhanced Mobility: Reduces joint and tissue stiffness, enabling better engagement in physical rehabilitation.\n\nStreamlined Regimen: Combines two therapeutic agents into a single convenient dosage form.\n\nUsage Guidelines\nThis medication must be taken strictly in accordance with a medical prescription.\n\nAdministration: Swallow the tablet whole with water. Do not crush, chew, or split the film-coated tablet.\n\nTiming: Take immediately after a meal to reduce potential gastrointestinal upset, unless directed otherwise by a doctor.\n\nCompliance: Complete the full course prescribed by your physician, and do not alter the recommended dosage.\n\nPotential Side Effects\nWhile generally well-tolerated, some individuals may experience mild side effects, including:\n\nGastrointestinal distress or mild nausea\n\nTransient dizziness or lightheadedness\n\nHeadaches\n\nGeneral fatigue or muscular weakness\n\nRare: Hypersensitivity reactions or cutaneous skin rashes (discontinue use and consult a physician immediately if severe symptoms appear).\n\nSafety Precautions and Considerations\nConsult a medical practitioner prior to initiating treatment if any of the following apply:\n\nPre-existing hepatic (liver) or renal (kidney) impairment\n\nKnown hypersensitivity to Tolperisone, Paracetamol, or related compounds\n\nPregnancy, plans for pregnancy, or active breastfeeding\n\nHistory of chronic alcohol dependency (due to increased liver sensitivity with Paracetamol)\n\nConcurrent use of other medications, particularly other products containing Paracetamol or central nervous system depressants\n\nStorage and Handling\nStore in a cool, dry area below 25°C (77°F).\n\nProtect from direct light, heat, and moisture.\n\nKeep strictly out of reach of children and pets.\n\nCheck the packaging expiration date before administration.\n\nFrequently Asked Questions\nWhat primary conditions does TOPERITIME P 150/325 treat?\n\nIt is indicated for short-term relief from acute musculoskeletal pain, muscle spasms, neck strains, backaches, and related orthopedic disorders.\n\nWhy is Tolperisone combined with Paracetamol?\n\nTolperisone eases muscle tightness at the neurological level, while Paracetamol lowers overall pain perception, creating a synergistic effect that addresses both spasm and pain together.\n\nWill this medication cause severe drowsiness?\n\nTolperisone is specifically designed to exert less sedating activity compared to older muscle relaxants. However, individual sensitivity varies, so caution is advised when driving or operating machinery until individual tolerance is established.\n\nIs TOPERITIME P 150/325 available over the counter?\n\nNo. It requires a valid medical prescription and direct supervision by a registered healthcare professional.", "price": 95.0, "discountamount": 29.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2493, "imageuri": "https://productimages.withfloats.com/actual/6a7722b0ed25653efa18364e.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a7722b0ed25653efa18364e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-08T12:35:59.075Z", "updatedon": "2026-08-08T12:35:59.075Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//tolperisone-hydrochloride-paracetamol-tablets/2493", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TOPERITIME P 150/325", "category": "ORTHOLOGYRANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a6def248b0777b5cb29791c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Propranolol Hydrochloride Sustained Release Capsules IP", "description": "PROPASULES LA 40 is a premium pharmaceutical formulation containing Propranolol Hydrochloride Sustained Release Capsules IP 40 mg. Developed with advanced sustained-release technology, this formulation delivers the active ingredient gradually over an extended period, helping maintain consistent therapeutic levels while supporting the convenience of once-daily administration when prescribed by a healthcare professional.\n\nManufactured in GMP-certified facilities using pharmaceutical-grade raw materials, PROPASULES LA 40 is produced under strict quality control measures to ensure purity, safety, and batch-to-batch consistency. It is intended for the treatment of medical conditions in which propranolol therapy is considered appropriate by a qualified physician.\n\nComposition\n\nEach Sustained Release Capsule Contains:\n\nPropranolol Hydrochloride IP – 40 mg\nSustained Release Pellets\nPharmaceutical Excipients – q.s.\nCapsule Shell – Approved pharmaceutical-grade ingredients\n\nDosage Form: Sustained Release Capsules\n\nWhat is PROPASULES LA 40?\n\nPROPASULES LA 40 contains Propranolol Hydrochloride, a non-selective beta-adrenergic receptor blocker (beta-blocker) that helps manage a variety of cardiovascular and neurological conditions. The sustained-release formulation is specifically designed to release the medicine gradually throughout the day, providing prolonged therapeutic action and helping maintain stable plasma drug concentrations compared with conventional immediate-release formulations.\n\nIts controlled-release technology enhances dosing convenience and supports consistent treatment outcomes when used according to medical advice.\n\nKey Features\nContains Propranolol Hydrochloride Sustained Release IP 40 mg\nAdvanced sustained-release technology for prolonged drug delivery\nSupports once-daily dosing as prescribed\nManufactured using premium pharmaceutical-grade ingredients\nProduced in GMP-compliant manufacturing facilities\nStringent quality assurance for consistent product performance\nReliable formulation for long-term therapeutic use under medical supervision\nTherapeutic Uses\n\nHealthcare professionals may prescribe PROPASULES LA 40 for the management of several cardiovascular and neurological disorders, including:\n\nHypertension (high blood pressure)\nChronic stable angina\nCardiac arrhythmias\nPrevention of migraine attacks\nEssential tremor\nPhysical symptoms associated with anxiety\nCardiovascular manifestations of hyperthyroidism\nSecondary prevention following myocardial infarction, when clinically indicated\n\nThe choice of treatment, dosage, and duration should always be individualized based on the patient's medical condition and physician's assessment.\n\nHow PROPASULES LA 40 Works\n\nPropranolol Hydrochloride works by blocking beta-adrenergic receptors located in the heart and other tissues. This action reduces the effects of adrenaline and other stress hormones on the cardiovascular system.\n\nAs a result, the medicine may help:\n\nSlow the heart rate\nReduce the workload on the heart\nLower elevated blood pressure\nImprove control of certain abnormal heart rhythms\nReduce the frequency of migraine episodes\nMinimize symptoms associated with essential tremor\nRelieve physical manifestations of anxiety, such as rapid heartbeat and trembling\n\nThe sustained-release pellets gradually release the medication throughout the day, providing prolonged therapeutic coverage and reducing fluctuations in drug levels.\n\nBenefits of the Sustained Release Formulation\n\nThe advanced sustained-release technology offers several advantages:\n\nControlled and gradual release of the active ingredient\nExtended therapeutic effect throughout the dosing interval\nMore consistent blood concentrations of the medication\nReduced peak-to-trough fluctuations compared with immediate-release formulations\nConvenient dosing schedule that may improve treatment adherence\nSuitable for long-term therapy under medical supervision\n\nTreatment outcomes depend on individual patient response and adherence to the prescribed regimen.\n\nDosage and Administration\n\nTake PROPASULES LA 40 exactly as instructed by your healthcare provider.\n\nGeneral recommendations include:\n\nSwallow the capsule whole with sufficient water.\nDo not crush, chew, or open the capsule unless specifically advised.\nTake the medicine at the same time every day.\nFollow the prescribed dosage schedule carefully.\nDo not discontinue treatment abruptly without consulting your physician, as sudden withdrawal may increase the risk of cardiovascular complications.\nPossible Side Effects\n\nLike all medications, PROPASULES LA 40 may cause side effects in some individuals, although many patients tolerate it well.\n\nCommon side effects may include:\n\nFatigue\nDizziness\nSlow heartbeat\nCold hands and feet\nNausea\nSleep disturbances\nMild stomach discomfort\n\nSeek immediate medical attention if you experience breathing difficulty, severe dizziness, fainting, swelling of the face or throat, or signs of a serious allergic reaction.\n\nConsult your healthcare provider if any side effects persist or become troublesome.\n\nPrecautions and Warnings\n\nBefore starting PROPASULES LA 40, inform your doctor if you have:\n\nAsthma or chronic obstructive pulmonary disease (COPD)\nDiabetes mellitus\nLiver impairment\nKidney disease\nHeart failure\nLow blood pressure\nBradycardia (slow heart rate)\nPeripheral vascular disease\nThyroid disorders\nHistory of hypersensitivity reactions\n\nYour physician should also be informed about all prescription medicines, over-the-counter drugs, herbal supplements, and dietary products you are taking to minimize the risk of drug interactions.\n\nPregnancy and Breastfeeding\n\nThe use of PROPASULES LA 40 during pregnancy or breastfeeding should only be considered when recommended by a qualified healthcare professional after carefully evaluating the potential benefits and possible risks.\n\nAlways consult your physician before taking this medicine during pregnancy or while nursing.\n\nStorage Instructions\n\nTo maintain product quality:\n\nStore in a cool and dry place.\nProtect from moisture and direct sunlight.\nKeep below the storage temperature specified on the product label.\nStore in the original packaging until use.\nKeep out of the reach of children.\nDo not use the medicine after the expiry date printed on the pack.\nWhy Choose PROPASULES LA 40?\n\nPROPASULES LA 40 is formulated to deliver dependable therapeutic performance through advanced sustained-release technology. Manufactured under stringent pharmaceutical quality standards, it combines consistent drug delivery, convenient dosing, and reliable product quality to support long-term cardiovascular and neurological care.\n\nKey Advantages\n\nPremium sustained-release Propranolol formulation\nControlled drug release for prolonged therapeutic action\nConvenient once-daily administration as prescribed\nManufactured in GMP-certified facilities\nHigh standards of quality, purity, and consistency\nReliable formulation for chronic disease management\nFrequently Asked Questions (FAQs)\nWhat is PROPASULES LA 40 prescribed for?\n\nPROPASULES LA 40 may be prescribed for conditions such as hypertension, chronic angina, cardiac arrhythmias, migraine prevention, essential tremor, anxiety-related physical symptoms, and certain cardiovascular conditions, depending on the physician's evaluation.\n\nCan PROPASULES LA 40 be taken once a day?\n\nYes. The sustained-release formulation is designed to support convenient once-daily dosing when prescribed by a healthcare professional.\n\nCan I stop taking PROPASULES LA 40 suddenly?\n\nNo. Abrupt discontinuation of propranolol may increase the risk of serious cardiovascular events. Always consult your doctor before stopping treatment.\n\nCan people with diabetes take PROPASULES LA 40?\n\nPatients with diabetes should use this medicine only under medical supervision, as beta-blockers may mask some warning signs of low blood sugar.\n\nIs PROPASULES LA 40 suitable for every patient?\n\nNo. This medicine may not be appropriate for individuals with certain conditions such as severe asthma, significant bradycardia, or specific cardiac disorders. Your healthcare provider will determine whether it is suitable for your individual medical needs.", "price": 45.0, "discountamount": 14.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2490, "imageuri": "https://productimages.withfloats.com/actual/6a6def271f223d84dee2d962.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a6def271f223d84dee2d962.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-01T13:05:40.676Z", "updatedon": "2026-08-01T13:05:40.676Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//propranolol-hydrochloride-sustained-release-capsules-ip/2490", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "PROPASULES LA 40", "category": "CARDIOLOGYRANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a50a30c9e1ef0fb4df551b0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "dorzolamide eye drops ip", "description": "Dorzolamide eye drops IP are a prescription ophthalmic solution used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Dorzolamide belongs to a class of drugs called carbonic anhydrase inhibitors, which work by reducing the production of aqueous humor (the fluid inside the eye), thereby lowering pressure within the eye. It is typically used two to three times daily and begins measurably lowering eye pressure within about 2 hours, though consistent long-term use is essential for sustained control. Common side effects include a temporary bitter or unusual taste in the mouth, burning or stinging on instillation, and blurred vision. Because dorzolamide is chemically a sulfonamide derivative, it should be used cautiously in patients with known sulfa allergies or significant kidney impairment, and only under an ophthalmologist's supervision. It is a Schedule H prescription-only medicine in India.\n\nWhat Is Dorzolamide Eye Drops IP?\nDorzolamide Eye Drops IP is a topical prescription medication used primarily to manage glaucoma and ocular hypertension — conditions characterized by abnormally elevated pressure inside the eye that, if left uncontrolled, can damage the optic nerve and lead to progressive, irreversible vision loss.\nThe “IP” designation indicates the formulation conforms to standards set out in the Indian Pharmacopoeia, ensuring consistent quality, purity, and potency.\nDorzolamide belongs to the carbonic anhydrase inhibitor (CAI) class of anti-glaucoma medications. Unlike oral carbonic anhydrase inhibitors (such as acetazolamide), which act systemically and often cause more pronounced side effects, topical dorzolamide is designed to act locally within the eye, offering effective IOP reduction with comparatively lower systemic exposure — though some systemic absorption can still occur.\nIt is frequently prescribed either as a standalone treatment or in combination with other IOP-lowering agents, such as beta-blockers (e.g., timolol) or prostaglandin analogues, when a single agent does not achieve adequate pressure control.\n\nHow Does Dorzolamide Work? (Mechanism of Action)\n\nAqueous humor production – The ciliary body inside the eye continuously produces aqueous humor, the clear fluid that maintains intraocular pressure and nourishes ocular tissues.\nCarbonic anhydrase enzyme – This enzyme, found in the ciliary body, plays a key role in the chemical reactions that generate bicarbonate ions, which drive fluid secretion into the eye.\nEnzyme inhibition – Dorzolamide inhibits carbonic anhydrase (specifically the II isoenzyme) within the ciliary processes.\nReduced fluid production – With the enzyme inhibited, bicarbonate-dependent fluid transport slows down, resulting in decreased aqueous humor formation.\nLowered intraocular pressure – Less fluid production means less pressure buildup inside the eye, helping protect the optic nerve from pressure-related damage over time.\n\n\nClinical Indications\nIndicationDetailsOpen-angle glaucomaPrimary indication; helps control chronic elevated IOPOcular hypertensionUsed to reduce elevated eye pressure even before glaucoma-related damage occursAdjunct therapyCombined with beta-blockers or prostaglandin analogues when monotherapy is insufficientPost-laser or post-surgical IOP spikesSometimes used short-term under specialist guidance\n\nDosage & Administration\nParameterRecommendationStandard dose (monotherapy)One drop in the affected eye(s), three times dailyStandard dose (with other IOP-lowering drops)Often reduced to twice daily when combined, per doctor's instructionsOnset of actionMeasurable IOP reduction typically begins within about 2 hoursPeak effectGenerally within a few hours of instillationIf using multiple eye dropsSpace different eye medications at least 10 minutes apartMissed doseApply as soon as remembered; skip if near the next scheduled dose — do not double upDuration of useLong-term, ongoing therapy as glaucoma is a chronic condition requiring continuous management\nNote: Consistency is critical — missed doses can allow intraocular pressure to rise, increasing the risk of progressive optic nerve damage.\n\nKey Benefits\n\nEffectively lowers intraocular pressure in both glaucoma and ocular hypertension\nActs locally in the eye, generally producing lower systemic side effects compared to oral carbonic anhydrase inhibitors\nCan be used as monotherapy or in combination with other classes of glaucoma medication for enhanced pressure control\nHelps protect the optic nerve from pressure-related damage with consistent long-term use\nAvailable in a well-established, pharmacopoeia-standardized formulation (IP grade)\nSuitable for long-term, chronic disease management in glaucoma patients\n\n\nPrecautions\n\nUse strictly as prescribed and do not adjust dosing without consulting your ophthalmologist\nInform your doctor if you have a known sulfonamide (sulfa) allergy, since dorzolamide is chemically related to sulfa drugs\nUse with caution in patients with significant kidney (renal) impairment, due to potential for systemic absorption\nNot typically recommended in patients with severe corneal disease without specialist evaluation\nIf using contact lenses, remove before instillation and reinsert only after the interval advised by your doctor\nRegular eye pressure monitoring and follow-up visits are essential during treatment\nInform your doctor of all other eye medications and systemic drugs you are using\nAvoid touching the dropper tip to the eye or any surface to prevent contamination\n\n\nSide Effects\nCommon (Usually Mild and Temporary)\n\nTemporary bitter or unusual taste in the mouth after application\nBurning or stinging sensation on instillation\nBlurred vision immediately after use\nEye redness or itching\nMild eye discomfort\n\nLess Common / Serious (Consult Your Doctor Promptly)\n\nSigns of an allergic reaction (rash, swelling, severe itching)\nPersistent eye pain or significant vision changes\nSigns of corneal problems (persistent redness, discharge, sensitivity to light)\nSystemic effects related to sulfonamide sensitivity, in rare cases\n\nIf any serious or persistent symptom occurs, discontinue use and contact your ophthalmologist immediately.\n\nComparison: Dorzolamide vs. Other Anti-Glaucoma Therapies\nTreatmentClassMechanismKey ConsiderationDorzolamide eye dropsCarbonic anhydrase inhibitorReduces aqueous humor productionSulfa-related caution; often used as adjunct therapyTimolol eye dropsBeta-blockerReduces aqueous humor production via a different pathwayCaution in asthma, heart conditionsLatanoprost / prostaglandin analoguesProstaglandin analogueIncreases aqueous humor outflowOnce-daily dosing; may darken iris/eyelash growthBrimonidineAlpha-2 agonistReduces production and increases outflowCan cause drowsiness, dry mouthOral acetazolamideSystemic carbonic anhydrase inhibitorReduces aqueous humor production systemicallyMore pronounced systemic side effects than topical dorzolamide\n\nKey Statistics (Placeholder — Pending Clinical Reviewer Verification)\nMetricValueAverage IOP reduction achieved with dorzolamide monotherapy[Placeholder – insert verified clinical trial statistic]Prevalence of open-angle glaucoma in adults over 40[Placeholder – insert epidemiological reference]Proportion of patients requiring combination glaucoma therapy[Placeholder – insert verified reference]\nAll statistics above are placeholders and must be verified and populated by a qualified clinical reviewer prior to publication.\n\nExpert Insight\n\n[Placeholder — Expert quote pending. To be added only after review and approval by a licensed ophthalmologist/medical reviewer associated with Steris Healthcare. Do not fabricate or publish without sign-off.]\n\n\nPrice of Dorzolamide Eye Drops IP\nThe price of dorzolamide eye drops IP varies depending on pack size, brand, and region. For current pricing, availability, and prescription verification, please consult your ophthalmologist or an authorized pharmacy.\nPrescription only – consult your doctor.\n\nConclusion\nDorzolamide Eye Drops IP play a well-established role in the long-term management of glaucoma and ocular hypertension, offering targeted, localized reduction of intraocular pressure through carbonic anhydrase inhibition. Whether used alone or alongside other classes of IOP-lowering medication, consistent, correctly timed use is essential to protect the optic nerve from progressive, irreversible damage. Because dorzolamide is a sulfonamide derivative with potential for systemic absorption, patients with sulfa allergies or kidney impairment should discuss suitability carefully with their ophthalmologist. As with all glaucoma therapy, regular monitoring and adherence to the prescribed regimen — rather than occasional or as-needed use — are what ultimately safeguard long-term vision.\n\nFrequently Asked Questions\n\n1. What is dorzolamide eye drops used for?\nDorzolamide eye drops are used to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, helping protect the optic nerve from pressure-related damage.\n\n2. How long does it take dorzolamide to lower eye pressure?\nDorzolamide typically begins measurably lowering intraocular pressure within about 2 hours of application, though consistent, long-term use is needed to maintain stable pressure control over time.\n\n3. What are the side effects of dorzolamide?\nCommon side effects include a temporary bitter or unusual taste in the mouth, burning or stinging upon application, blurred vision, and mild eye redness or discomfort. Less commonly, allergic reactions or persistent eye irritation can occur and should be reported to a doctor.\n4. Does dorzolamide affect the kidneys?\nDorzolamide is a sulfonamide derivative, and although it is applied topically with generally low systemic absorption, caution is advised in patients with significant kidney impairment. Patients with known kidney disease or sulfa allergies should inform their doctor before starting treatment.\n\n5. How often should dorzolamide eye drops be used?\nDorzolamide is typically used three times daily as monotherapy, or twice daily when combined with other glaucoma medications, exactly as directed by your ophthalmologist.\n\n6. Can dorzolamide be used with other glaucoma eye drops?\nYes, dorzolamide is commonly combined with beta-blockers, prostaglandin analogues, or other IOP-lowering agents when a single medication does not achieve adequate pressure control. Different eye drops should be spaced at least 10 minutes apart.\n\n7. Is dorzolamide safe for long-term use?\nYes, dorzolamide is designed for long-term, ongoing use in chronic glaucoma management, provided it is used under regular ophthalmologist supervision with periodic eye pressure monitoring.\n\n8. Who should not use dorzolamide eye drops?\nPatients with known hypersensitivity to sulfonamides, significant kidney impairment, or specific contraindications identified by their doctor should use dorzolamide only under close medical supervision, if at all.\n\n9. Does dorzolamide cause blurred vision?\nTemporary blurred vision can occur immediately after applying dorzolamide. This is usually short-lived, but if it persists, you should consult your ophthalmologist.\n\n10. Can dorzolamide eye drops be used with contact lenses?\nIt's generally recommended to remove contact lenses before applying dorzolamide and reinsert them only after the interval advised by your doctor, as certain preservatives in eye drops can affect contact lens materials.\n\n11. What happens if I miss a dose of dorzolamide?\nApply the missed dose as soon as you remember, unless it is almost time for your next scheduled dose — in that case, skip the missed dose and continue your regular schedule. Do not double up doses.\n\n12. Why does dorzolamide cause a bitter taste?\nThe bitter taste occurs because a small amount of the eye drop drains through the tear duct into the nasal passage and throat, where it can be tasted. This is a recognized, generally harmless effect of topical carbonic anhydrase inhibitors.\n13. Is dorzolamide the same as timolol eye drops?\nNo. Dorzolamide is a carbonic anhydrase inhibitor, while timolol is a beta-blocker. Both lower eye pressure but through different mechanisms, and they are sometimes prescribed together for enhanced effect.\n\n14. Can dorzolamide be used during pregnancy?\nUse during pregnancy or breastfeeding should only occur under direct medical supervision. Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding before starting dorzolamide.\n\n15. How is dorzolamide different from oral glaucoma medications?\nTopical dorzolamide acts locally in the eye and generally causes fewer systemic side effects than oral carbonic anhydrase inhibitors like acetazolamide, which act throughout the body and can cause more pronounced systemic effects.\n16. Can stopping dorzolamide suddenly cause problems?\nStopping dorzolamide abruptly can allow intraocular pressure to rise again, increasing the risk of progressive optic nerve damage. Always consult your ophthalmologist before discontinuing treatment.\n\n17. Does dorzolamide need to be refrigerated?\nStorage requirements can vary by brand and formulation; always follow the storage instructions printed on your specific product's packaging or as advised by your pharmacist.", "price": 350.0, "discountamount": 105.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2470, "imageuri": "https://productimages.withfloats.com/actual/6a50a30e9569e07de66607f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a50a30e9569e07de66607f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-07-10T07:45:16.262Z", "updatedon": "2026-07-10T07:45:16.262Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//dorzolamide-eye-drops-ip/2470", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CIPVISION DORZONIX 2%", "category": "Opthalmology Range", "tags": [ "dorzolamide eye drops ip", "dorzolamide eye drops", "dorzolamide eye drops uses", "dorzolamide eye drops uses in hindi", "dorzolamide eye drops price", "dorzolamide eye drops ip", "dorzolamide eye drops brand name", "dorzolamide eye drops brands" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }